Media & Press

  • Phebra Establishes New Subsidiary In Canada And Announces Marketing Approval For IV Arsenic Trioxide Solution

    Phebra has continued its international business expansion with the opening of its subsidiary in Montreal, Canada.

    May 2019

  • Phebra Expands Head Office

    Phebra has announced a $4 million expansion of its Sydney multi-purpose sterile injectables site.

    March 2019

  • Phebra Launches New Brand of Phosphate Tablets

    Phebra has launched its own brand of Phosphate 500 mg effervescent tablets to replace the discontinued Phosphate Sandoz effervescent tablets.

    December 2018

  • Phebra Announces UK Subsidiary Company

    Phebra is pleased to announce the expansion of its international operations, with the establishment of new wholly-owned subsidiary company in the United Kingdom (UK).

    November 2018

  • Oral Arsenic Formulation for Treatment of Acute Promyelocytic Leukaemia (APL)

    Australian pharmaceutical manufacturer Phebra, is pleased to announce its development of an innovative oral arsenic trioxide formulation for the treatment of APL.

    April 2018

  • Phebra Welcomes PBS Listing of Benzatropine Injection

    Phebra is pleased that its Australian made Benzatropine Injection (benzatropine mesilate) is now accessible via the Pharmaceutical Benefits Scheme (PBS).

    March 2018

  • Phebra Welcomes PBS Listing of Narcan® Injection

    Phebra has welcomed the listing of the lifesaving Narcan® Injection (naloxone hydrochloride) on the Australian Pharmaceutical Benefits Scheme (PBS).

    February 2018

  • New Study Shows Benefits of Caffeine For Pre-Term Babies

    Phebra has welcomed the findings of a landmark new study which shows the sustained benefits of giving neonatal caffeine to pre-term babies suffering breathing difficulties.

    July 2017

  • Sodium Bicarbonate US Supply Agreement

    Phebra has entered into a commercial agreement to supply Sodium Bicarbonate Injection to the US to assist with a shortage in the US hospital market.

    January 2017

  • Phebra Welcomes PBS Listing for Leukaemia Treatment

    Phebra has welcomed the listing on the Australian PBS of its PHENASEN® (arsenic trioxide) Injection for the first line treatment of newly-diagnosed acute promyelocytic leukaemia (APL).

    April 2016